SCREENING STANDARDS. The Board and the Union, in consultation with the Medical Provider, have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: INITIAL CONFIRMATION XXXX XXXXXXXXX XXXXX XXXXX XXXXXXXXXXXX 0000 ng/ml 300 ng/ml BARBITURATES 200 ng/ml 500 ng/ml BENZODIAZEPINES 200 ng/ml 300 ng/ml CANNABINOIDS 100 ng/ml 15 ng/ml COCAINE METABOLITE 300 ng/ml 150 ng/ml METHADONE 300 ng/ml 300 ng/ml METHAQUALONE 300 ng/ml 300 ng/ml OPIATES 300 ng/ml* 300 ng/ml *25 ng/ml if immunoassay specific for free morphine PHENCYCLIDINE (PCP) 25 ng/ml 25 ng/ml PROPOXYPHENE 300 ng/ml 300 ng/ml OXYCONTIN 100 ng/ml 100 ng/ml Should NIDA add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to confirm to NIDA standards. Employees will be notified, in writing, of such changes, within 60 days prior of its implementation. All test results shall be protected as confidential medical information as appropriate under the Americans With Disabilities Act (i.e., the test results shall be provided on a right to know basis - the employee, the Employer and the substance abuse professional - and the results shall not be presented until analyzed by a Medical Review Officer).
SCREENING STANDARDS. 1. There shall be a five-panel screening and the substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: Type of Drug or Metabolite Standard Initial Test Ng/ml Confirmation Test Marijuana Delta-9-tetrahydrocanna-binol- 9-carboxylic acid (THC) 50 15 Cocaine 300 150 Phencyclidine (PCP) 25 25 Amphetamines Amphetamine 1000 500 Methamphetamine 500(a) Opiate metabolites Codeine Morphine 6-acetylmorphine (6-AM) 2000 2000 2000 10(b) Specimen must also contain amphetamine at a concentration of greater than or equal to 200ng/ml. Test only conducted when specimen contains morphine at a concentration greater than or equal to 2000 ng/ml.
SCREENING STANDARDS. Service Provider shall employ commercially reasonable standards for identity verification and authentication of Subscribers prior to enrolling Subscribers in the Service Provider Services. [****]
SCREENING STANDARDS. The City and Local #330 in consultation with the Medical Provider have determined the type of screening to be used. The only substances to be tested for and the threshold substance levels that shall be considered a positive test result are as follows: Drug Initial Screening Confirmation Cutoff (ng/ml) Cutoff(ng/ml) Amphetamines* 500 ng/ml 250 ng/ml Barbiturates 300 ng/ml 300 ng/ml Benzodiazepines 300 ng/ml 300 ng/ml Cannabinoids* 50 ng/ml 15 ng/ml Cocaine* 150 ng/ml 100 ng/ml Methadone 300 ng/ml 300 ng/ml Opiates* 2000 ng/ml 2000 ng/ml Phencyclidine* 25 ng/ml 25 ng/ml Propoxphene 300 ng/ml 300 ng/ml * Found in the 5-panel urine drug screen Should SAMHSA or the Department of Health and Human Services (DHHS) add to or delete from the current panel of controlled substances or alter the initial screening or confirmation levels, this program will be modified to conform to such standards. Employees will be notified, in writing, of such changes.
SCREENING STANDARDS. The Township and the Union in consultation with the Medical Provider have determined the type of screening to be used. The only substances to be tested for, and the threshold substance levels that shall be considered a positive test result are as follows: APPENDIX C (CONTINUED) DRUG INITIAL SCREENING XXXXX XXXXXXXXXXXX XXXXX Xxxxxxxxxxxx 0000 ng/ml 500 ng/ml Barbiturates 500 ng/ml 200 ng/ml Benzodiazepines 300 ng/ml 300 ng/ml Cannabinoids 100 ng/ml 15 ng/ml Cocaine Metabolite 300 ng/ml 150 ng/ml 6-Acetylmorphine (Heroin) 10 ng/ml 10 ng/ml Methadone 300 ng/ml 300 ng/ml Methaqualone 300 ng/ml 300 ng/ml Opiates 300 ng/ml 300 ng/ml* Phencyclidine (PCP) 25 ng/ml 25 ng/ml Propoxyphene 300 ng/ml 300 ng/ml *25 ng/ml if immunoassay specific for free morphine
